
Anlon Healthcare Q4 Results Preview: Earnings Growth, Key Expectations & Outlook
Updated: 20 Mar 2026 • 3:24 pm
Posted by:

Anlon Healthcare Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Anlon Healthcare was listed on the National Stock Exchange (NSE) on 03-Sep-2025. Anlon Healthcare share has its face value of 10 per share, and its NSE symbol is AHCL. The company operates in the Healthcare sector and primarily belongs to the Pharmaceuticals industry.
Anlon Healthcare Q4 Results 2026 Preview
- Anlon Healthcare Q4 FY26 revenue is expected to be around Moderate Growth Expected, representing a 10-13% YoY increase compared to the same quarter last year.
- Profit After Tax, or PAT, is projected to rise 11-15% YoY.
- EBITDA to rise 10-14%.
- Anlon Healthcare is expected to show Moderate Growth Expected in its revenue.
Click and Sign Up to Get Live Updates on Q4 Results
Anlon Healthcare Share Performance
- Over the past six months, Anlon Healthcare share price has Up by 20% to 114.89.
- Moreover, over the past year, the stock has Up by 34%
- Despite this weak short-term performance, Anlon Healthcare stock has delivered a financially sound 160% return over the past 5 years.
- As of today, 20-03-2026, the Anlon Healthcare share price is trading at 114.89 per share.
Key Factors to Watch for Anlon Healthcare Q4 Results FY26
- Revenue Growth & Segment Performance – Focus on topline growth in the Pharmaceuticals industry within the Healthcare sector.
- Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
- Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
- Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
- Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.
About Anlon Healthcare
Anlon Healthcare specializes in the distribution and marketing of pharmaceutical products, medical devices, and healthcare consumables, catering to hospitals, clinics, and healthcare providers. The company focuses on supplying quality healthcare solutions within the Indian market.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Final Thoughts
Anlon Healthcare is gear up to announce its Q4 FY26 results. Analysts expect 10-13% revenue growth, a 11-15% rise in PAT, and a 10-14% rise in EBITDA. Anlon Healthcare focuses on revenue growth from order execution, margin improvement, a strong order book, and management.
Stay informed with Univest blogs to get real-time updates on Anlon Healthcare Q4 results FY26.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Siemens Energy Q4 FY26 Earnings Preview Expectations Outlook
Entertainment Network Q4 FY26 Earnings Preview Outlook
Energy Development Q4 FY26 Earnings Preview Outlook
Endurance Technologies Q4 FY26 Earnings Preview Expectations Outlook
Recent Articles

Top Stocks to Buy for Long Term: Bharti Airtel, Kotak Bank, Eternal Among 9 Stocks Experts Suggest, Check Target Price
13 October 2026

Hong Kong Stock Market: Hang Seng Index Recovers From Intraday Losses, Extends Gains for 3rd Day, What Gave It a Boost?
13 October 2026

Ramkrishna Forgings Share Price Up 34% in 2026: Monarch Networth Sees 18% Upside With Rs 806 Target, Here's Why
13 October 2026

RIL Target Price Ahead of Jio Initial Public Offering: 47% Upside, Why Religare Recommends Buying the Mukesh Ambani Stock Before Issue Launch
13 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Top Stocks to Buy for Long Term: Bharti Airtel, Kotak Bank, Eternal Among 9 Stocks Experts Suggest, Check Target Price
Hong Kong Stock Market: Hang Seng Index Recovers From Intraday Losses, Extends Gains for 3rd Day, What Gave It a Boost?
Ramkrishna Forgings Share Price Up 34% in 2026: Monarch Networth Sees 18% Upside With Rs 806 Target, Here's Why
RIL Target Price Ahead of Jio Initial Public Offering: 47% Upside, Why Religare Recommends Buying the Mukesh Ambani Stock Before Issue Launch
Moneyview Share Price: Newly Listed Stock Gives 83% Returns in 13 Days, Should You Hold for More Gains or Book Profits?
Popular this week
Up 75% in 6 Months, India Glycols Shares Surge 14% Today: Should You Buy? Experts Decode the India Glycols Share Price Rally

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





